CPHI Online is the largest global marketplace in the pharma ingredients industry

  • Products
    0
  • Companies
    0
  • Articles
    0
  • Events
    0
  • Webinars
    0
Read more about CPHI

LEVOFLOXACIN MESYLATE FOR INJECTION

LEVOFLOXACIN MESYLATE FOR INJECTION
Product Description

strength 0.2g, 0.3g

It suitable for moderate or severe infections caused by sensitive bacterial, including respiratory system infection, acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bacterial bronchitis, bronchiectasis, pneumonia, tonsillitis,etc.

Read more Show less

AZ Pharmaceutical Group Limited

  • CN
  • 2017
    On CPHI since
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    International Approvals/Standards
  • Supplied from
    China
  • Measured In
    piece
More specifications Fewer specifications
Sales Markets
Show more Show less

AZ Pharmaceutical Group Limited

  • CN
  • 2017
    On CPHI since
View company profile

More Products from AZ Pharmaceutical Group Limited (2)

  • DAPTOMYCIN FOR INJECTION, 0.5g

    Product DAPTOMYCIN FOR INJECTION, 0.5g

    For treatment of bloodstream infection (bacteremia) associated with right infective endocarditis caused by Staphylococcus aureus(including methicillin sensitivity and methicillin resistance). 

     

  • DOXOFYLLINE FOR INJECTION, 0.1g

    Product DOXOFYLLINE FOR INJECTION, 0.1g

    Suitable for Dyspnea due to bronchial asthma, chronic bronchitis and other bronchospasm .

Recommended Products

  • Sterile drug product CDMO services

    Product Sterile drug product CDMO services

    Thermo Fisher Scientific's flexible aseptic manufacturing and sterile fill finish solutions for your molecule's unique needs and challenges will enable success in early development, late-phase, and commercial manufacturing.

    Thermo Fisher offers extensive sterile product development and commercial ...
  • Cisplatin

    Product Cisplatin

    CISPLATIN 50 mg lyophilized vials – Several types of cancer (testicular, ovarian…). Authorized EU-CTD Dossier
  • Formulation Development

    Product Formulation Development

    BioDuro-Sundia holds more than 25 years of experience formulating poor solubility and  poor permeability drugs for the clinical studies. Our comprehensive suite of advanced formulation technologies and extensive scientific know-how supports >95% of marketed dosage form...